Comparison of outcomes using the rituximab originator MabThera with the biosimilar Truxima in patients with ANCA-associated vasculitis
Author:
Affiliation:
1. Department of Renal Medicine, Royal Free Hospital, University College London, London, UK
2. Pharmacy Department, Royal Free Hospital, London, UK
3. Department of Renal Medicine, University Hospital Birmingham, Birmingham, UK
Publisher
Informa UK Limited
Subject
Immunology,General Medicine,Immunology and Allergy,Rheumatology
Link
https://www.tandfonline.com/doi/pdf/10.1080/03009742.2021.1926318
Reference16 articles.
1. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
2. Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
3. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis
4. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial
5. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Biosimilar in Cervical Cancer;Biosimilars for Cancer Treatment;2024
2. AB0775 EFFECTIVENESS AND SAFETY OF NON-MEDICAL SWITCH FROM RITUXIMAB ORIGINATOR TO AND AMONG BIOSIMILARS IN SMALL VESSEL VASCULITIDES PATIENTS: REAL WORLD DATA FROM A RETROSPECTIVE MONOCENTRIC STUDY;Scientific Abstracts;2023-05-30
3. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update;Annals of the Rheumatic Diseases;2023-03-16
4. Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience;Internal and Emergency Medicine;2023-02-24
5. A Developer’s Perspective on Clinical Evidence and Benefits for Rituximab Biosimilar Uptake, with a Focus on CT-P10;Clinical Drug Investigation;2022-03-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3